Mississauga, ON -- (SBWIRE) -- 10/11/2013 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “FDA Approves Medicure sNDA for Blood Thinner Drug Aggrastat.”
Companies mentioned in this article include Eli Lilly (NYSE:LLY), AstraZeneca (NYSE:AZN) and Medicure Inc. (TSX-Venture:MPH) (OTCQB:MCUJF).
Thrombotic cardiovascular events present a significant risk to heart patients, providing for several blockbuster blood-thinning drugs to emerge in recent years. In 2012, the race to produce new drugs in this area stepped it up a notch with the expiration of the patents on Sanofi and Bristol-Myers Squibb’s heavily used Plavix.
When Plavix went off patent, it put pressure on other blood thinning drugs, such as Eli Lilly’s (NYSE:LLY) Effient, AstraZeneca’s (NYSE:AZN) Brilinta and Medicure Inc.’s (TSX-Venture:MPH) (OTCQB:MCUJF) Aggrastat as payers looked for patients to start using cheaper generics. A smaller specialty pharmaceutical company, Winnipeg, Manitoba-based Medicure markets Aggrastat (tirofiban) in the United States, while Correvio International has license for the rest of the world.
Aggrastat, an injectable antiplatelet drug approved in combination with heparin, is indicated for the treatment of acute coronary syndrome. Clinical data showed the cocktail of Aggrastat and heparin to lower the risk of myocardial infarction and death by 43 percent compared to heparin alone in the week following therapy.
The full version of this article can be found at:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.